Saturday 17 October 2026 Export BIMI’s income statement to Excel — free account

BIMI Holdings Inc.

BIMI Healthcare Pharmaceutical Retailers

0.00 0.00 NaN

Follow BIMI

Alert me

Market cap: $170.0K
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: −3.75
Beneish M: −5.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 76.98%

Capital & Financial Ratios $m

Market Cap 0.17

Revenue 12.63

Net Income (10.55)

Free Cash Flow (3.71)

Net Debt (0.83)

Current Ratio 1.21

Debt/Equity 0.02

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2020	2021	2022	Q'23
Cash	0	5	2	1
Receivables	7	6	3	4
Inventory	1	2	8	7
Other	3	3	7	9
	25	21	23	24

	2020	2021	2022	Q'23
Payables	6	6	15	11
ST’ Debt	3	0	0	0
Other	0	2	1	1
	16	22	25	20

Compound Annual Growth %

	10y	5y	3y
Sales	2.47%	6.82%	321.48%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(16.00%)	(28.18%)	(15.06%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	6	3	—	—
’22	3	3	5	1	12
’21	2	9	14	—	21
’20	0	4	3	6	13
’19	1	0	0	0	0
’18	0	1	1	5	7
’17	1	2	1	5	9

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(1)	(1)	—	—
’22	(5)	2	(3)	(4)	(10)
’21	(2)	(2)	1	(2)	(4)
’20	(1)	(3)	1	(1)	(4)
’19	0	0	(1)	(1)	(2)
’18	1	(1)	1	(1)	0
’17	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(1)	(2)	—	—
’22	(5)	2	(3)	(4)	(10)
’21	(2)	(2)	0	0	(5)
’20	(1)	(3)	0	(4)	(7)
’19	0	0	(1)	(1)	(2)
’18	1	(1)	1	(1)	0
’17	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.23)	0.23	(0.51)	—	—
’22	(0.29)	(1.80)	(1.60)	(7.28)	(8.38)
’21	(10.00)	(0.50)	(0.63)	(54.08)	(65.10)
’20	(12.00)	23.00	(9.50)	(10.97)	(9.00)
’19	(3.58)	(5.50)	(3.50)	(14.64)	(27.00)
’18	(3.50)	(11.00)	(2.00)	(97.18)	(113.68)
’17	(3.00)	(2.00)	(3.00)	(3.50)	(11.00)

Fiscal quarters ending in the months shown.

Group	Line	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023e
Price, $
Price, $	Low	—	—	—	26.05	38.00	43.00	51.50	75.00	23.60	1.07	Analyst estimates 2023–2025 Powerpack
	High	—	—	—	109.50	79.00	1,250.00	1,035.00	370.00	140.50	27.00
People
People	Employees	—	—	—	220	220	81	110	222	524	296
	Revenue/emp, $m	—	—	—	0.03	0.04	0.08	0.00	0.06	0.04	0.04
Income, $m
Income, $m	Revenue	—	—	—	6	9	7	0	13	21	12
	Gross margin, %	—	—	—	2.46	10.77	7.02	(92.47)	19.02	11.38	16.48
	EBT	—	—	—	(2)	(2)	0	(2)	(3)	(35)	(22)
	EBT margin, %	—	—	—	(30.08)	(18.52)	(3.25)	(972.15)	(26.09)	(162.59)	(182.77)
	Net income	—	—	—	(2)	(2)	0	(2)	(4)	(35)	(22)
	Depreciation	—	—	—	1	1	1	0	2	2	3
Per share, $
Per share, $	Revenue	—	—	—	45.94	60.13	43.76	0.97	60.16	39.78	4.44
	Earnings	—	—	—	(14.00)	(11.00)	(110.83)	(27.00)	(9.00)	(65.10)	(8.38)
	Cash flow	—	—	—	1.22	(6.42)	(2.30)	(12.64)	(16.48)	(8.28)	(3.85)
	Capex	—	—	—	(3.10)	0.00	0.00	0.00	(15.57)	(0.45)	0.00
	Free cash flow	—	—	—	(1.88)	(6.42)	(2.30)	(12.64)	(32.05)	(8.73)	(3.85)
	Book value	—	—	—	203.10	192.91	66.79	52.10	79.13	21.15	1.96
	Shares, m	—	—	—	0	0	0	0	0	1	3
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.95	0.86	17.97	35.38	1.39	0.64	0.31
	P/B	—	—	—	0.21	0.27	11.78	3.06	1.06	1.21	0.70
	EV/Sales	—	—	—	1.88	1.67	18.83	35.52	1.70	0.47	0.15
	EV/FCF	—	—	—	7.51	(10.85)	(363.75)	(13.04)	(3.21)	(2.13)	(0.17)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	0	(1)	0	(2)	(4)	(4)	(10)
	Capex	—	—	—	0	—	—	—	(3)	0	—
	Free cash flow	—	—	—	0	(1)	0	(2)	(7)	(5)	(10)
Balance, $m
Balance, $m	Working capital	—	—	—	5	5	10	9	10	(1)	(2)
	Total debt	—	—	—	6	7	6	0	4	1	0
	Net debt	—	—	—	6	7	6	0	4	(4)	(2)
	Shareholders’ equity	—	—	—	27	27	10	9	17	11	5
Returns, %
Returns, %	ROA	—	—	—	(4.45)	(3.99)	(52.06)	(16.71)	(6.31)	(98.10)	(60.65)
	ROIC	—	—	—	(2.86)	(2.18)	(0.85)	(7.15)	(11.43)	(261.26)	(290.38)
	ROE	—	—	—	(6.37)	(5.81)	(90.05)	(47.99)	(15.72)	(247.86)	(270.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Sep 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HITI High Tide Inc.	$228.2M	— (loss-making)	92.0×	+30.72% (above 0%: growing)	+800.00% (above 0%: growing)	−7.91% (below 0%: shrinking)	26.53%	4.38%	Compare
PETS PetMed Express, Inc.	$26.4M	— (loss-making)	24.0×	−19.86% (below 0%: shrinking)	n/m	+38.60% (above 0%: growing)	27.63%	(15.19%)	Compare
MEDS DataMeds AI, Inc	$12.8M	— (loss-making)	—	−77.15% (below 0%: shrinking)	n/m	−41.85% (below 0%: shrinking)	10.24%	(412.67%)	Compare
SCNX Scienture Holdings, Inc.	$5.6M	— (loss-making)	— (loss-making)	+3,235.92% (above 0%: growing)	n/m	−53.98% (below 0%: shrinking)	97.73%	(785.71%)	Compare
POM Pomdoctor Limited - Sponsored ADR	$5.0M	—	—	—	—	—	—	—	Compare
RDGT Ridgetech Inc.	$3.0M	— (loss-making)	— (loss-making)	+113.14% (above 0%: growing)	n/m	+4,848.31% (above 0%: growing)	22.81%	0.00%	Compare
MDVLQ MedAvail Holdings, Inc.	$2.9M	— (loss-making)	— (loss-making)	−25.41% (below 0%: shrinking)	n/m	+66.32% (above 0%: growing)	43.95%	(1,099.75%)	Compare
BIMI BIMI Holdings Inc.	$170.0K	— (loss-making)	—	−48.85% (below 0%: shrinking)	n/m	+28.06% (above 0%: growing)	4.57%	(124.83%)
Median of peers	$5.6M	—	—	+5.43%	—	+15.35%	27.08%	(213.93%)

All 8 Pharmaceutical Retailers stocks →